Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Peripheral Blood Biomarkers for Predicting Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: A Single-Center Prospective Observational Cohort Study

NCT07734857 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.

NCT NCT07734857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07734857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Peripheral Blood Biomarkers for Predicting Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: A Single-Center Prospective Observational Cohort Study
Lead sponsor
Shanghai Zhongshan Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
July 10, 2026
Completion date
July 30, 2028
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)